Xynomic Pharmaceuticals, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO100%
Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +50.5 months). See all sponsors →
Open Xynomic Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Abexinostat NCT04024696 |
P1/2 | Active, not recruiting | Non Hodgkin Lymphoma | 12 | 2024-12-30 (+50 mo) |
| Abexinostat NCT03934567 |
P2 | Active, not recruiting | Lymphoma, Follicular | 87 | 2025-01-29 |
| abexinostat NCT03936153 |
P2 | Recruiting | Diffuse Large B-cell Lymphoma (DLBCL) | 170 | 2026-07-31 (+40 mo) |
| Pazopanib NCT03592472 |
P3 | Recruiting | Renal Cell Carcinoma | 413 | 2026-12-30 (+59 mo) |
| ENHANCE NCT05275374 |
P1/2 | Not yet recruiting | Cancer; BRAF V600 Mutation | 221 | 2027-12-30 (+37 mo) |
| FORERUNNER NCT03600441 |
P2 | Active, not recruiting | Follicular Lymphoma | 139 | 2027-12-31 (+108 mo) |